receptor agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-13. Numbers and descriptions here follow the published literature rather than marketing material.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
As there are more customers using cards and mobile apps, Starbucks has decided to reduce the amount of stores that use cash. However, for the elderlies and foreigners, they do accept cash in rare occasions. This is not only to apply the newest technology to the stores, but to apply the change of lifestyle, making it convenient for both the customers and partners. Starbucks Korea said October 16, 2024. it has partnered with the country's leading retail lender KB Kookmin Bank to introduce account-based settlement services for its customers in the first quarter of next year. Starbucks Korea announced on the 28th Oct. that it will increase the prices of 11 tall (355ml) iced beverages on its menu from the 1st of next month. The price increase will include two blended drinks, six frappuccinos, one physio, and two refreshers, each of which will increase by 200 won.
=== Reduction of endogenous quinones === NQO1 plays a role in ubiquinone and vitamin E quinone metabolism. These quinones protect cellular membranes from peroxidative injury in their reduced state. Furthermore, reduced forms of ubiquinone and vitamin E quinone have been shown to possess antioxidant properties that are superior to their non-reduced forms.
GC Vitamin D binding protein, also referred to as Vitamin D binding protein (DBP), is a protein that is encoded by the GC gene in Homo sapiens (modern humans). DBP is genetically the oldest member of the albuminoid family and appeared early in the evolution of vertebrates.
He began his campaign by defeating home favourite Matteo Berrettini who retired with an injury. On his way to the title he defeated the top two seeds Djokovic and Medvedev in the semifinals and finals respectively. Due to this win, he became the only player active to have won multiple ATP Finals titles (2) other than Djokovic and Roger Federer, with 7 and 6, respectively.
== Treatment == SAAM is treated by stopping the offending statin medication and taking immunosuppressive medications. In rare cases, affected people spontaneously improve after just stopping the implicated statin. However, most cases mandate the use of immunosuppressive medication. Corticosteroids are considered first-line treatment. Prednisone dosed at 1 milligram/kilogram of body weight daily is generally recommended. Corticosteroid therapy alone may be reasonable in cases of mild muscular weakness. More severe cases require the use of combined methotrexate, azathioprine, or mycophenolate with corticosteroids. Severe cases of SAAM may fail to respond to 8–12 weeks of combination therapy. Rituximab or intravenous immunoglobulin are recommended as add-on therapy in such cases. Intravenous immunoglobulin is an appropriate first-line therapy in select individuals. Suitable candidates for first-line intravenous immunoglobulin include people who have diabetes mellitus or who wish to avoid corticosteroid therapy.
Sources: en.wikipedia.org
By the end of 2017, it was announced that Catherine Keener would star opposite Carrey in Kidding. The series lasted two seasons. Carrey was also the subject of two documentaries in 2017. The first, a short subject entitled I Needed Color about his lifelong passion for art, was released online in the summer. Later that year another documentary, Jim & Andy: The Great Beyond—Featuring a Very Special, Contractually Obligated Mention of Tony Clifton, premiered at The Venice Film Festival and was later picked up by Netflix. The film chronicles the behind-the-scenes drama during the shooting of Man on the Moon, when he never broke character as Andy Kaufman. It incorporates footage that was shot for the film's electronic press kit but ultimately pulled by Universal as they felt that it was too damaging.
=== Human use === Nitrofurazone was previously available as a prescription in the U.S., and was indicated as a topical solution, topical cream, or topical ointment for the treatment of bacterial skin infections, wounds, burns, and ulcers. It was also used as a prophylactic measure to prevent infection that could potentially result in skin graft rejection. Nitrofurazone is still very popular as a topical solution for the treatment of tonsillitis in Russia.
=== Views on golf === In July 2007, Player made statements at the Open Championship golf tournament about the use of performance-enhancing drugs in golf. He alleged that at least ten players were "taking something", citing human growth hormone, steroids and creatine as possible substances. Both the PGA Tour and European Tour were in the process of introducing random testing programmes at the time. In June 2016, in an interview with bunkered.co.uk, Player branded as "laughable" a report released by the R&A and USGA governing bodies which said that driving distance in golf was only increasing minimally. He warned of a "tsunami coming" due to the governing bodies' failure to address issues surrounding new golf technology. After the 2017 Alfred Dunhill Links Championship, Player reiterated these comments, taking to messaging service Twitter to say he was sad to see the Old Course at St Andrews "brought to her knees" after Ross Fisher broke the course record on a day of very low scoring during the final round.
During character creation, each upgrade costs one point. The upgrade cost increases as the game progresses. Each ability can be raised from zero to five, and it is impossible to accrue enough experience points to complete every skill (allowing the player to specialize or balance their character). Experience points are gained by completing quests, finding items, or unlocking secret paths rather than killing enemies and are used to increase or unlock the character's statistics and abilities. The game features a main story and optional side quests that can be completed at any time; the player can move between the available areas at will to revisit locations, characters, or merchants. The player's clan affects their skills and powers. Although the attractive Toreadors receive bonuses for seduction and persuasion, opening additional dialogue options, they are physically weak; the Nosferatu are forced to travel in the shadows or through sewers to avoid alerting humans but receive bonuses to their intelligence and computer skills, which enables access to more information. The Malkavians have different dialogue options, reflecting their inherent insanity. Upgrading some skills provides additional dialogue options; attractive and charismatic characters seduce to get their way, aggressive characters threaten, and others persuade their targets to cooperate.
Pituitary adenylate cyclase-activating polypeptide type 1 receptor InterPro: IPR002285 PACAPR (ADCYAP1R1) Calcitonin receptor InterPro: IPR003287 CALCR Calcitonin receptor-like receptor InterPro: IPR015476 CALCRL Corticotropin-releasing hormone receptor InterPro: IPR003051 CRHR1; CRHR2 Glucose-dependent insulinotropic polypeptide receptor/Gastric inhibitory polypeptide receptor InterPro: IPR001749 GIPR Glucagon receptor InterPro: IPR003291 GCGR Glucagon receptor-related InterPro: IPR003290 GLP1R; GLP2R; Growth hormone releasing hormone receptor InterPro: IPR003288 GHRHR Parathyroid hormone receptor InterPro: IPR002170 PTHR1; PTHR2 Secretin receptor InterPro: IPR002144 SCTR Vasoactive intestinal peptide receptor InterPro: IPR001571 VIPR1; VIPR2
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.